Remove Drug Research Remove Drugs Remove Research
article thumbnail

BioAge prices $198M IPO, validating pivot to obesity drug research

BioPharma Drive: Drug Pricing

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.

article thumbnail

AltruBio lands up to $225M after shift to immune drug research

BioPharma Drive: Drug Pricing

Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmas form joint venture to jumpstart Japanese drug research

BioPharma Drive: Drug Pricing

A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.

article thumbnail

Foundery, a new biotech venture firm, sets out to speed early immune drug research

BioPharma Drive: Drug Pricing

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

article thumbnail

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

BioPharma Drive: Drug Pricing

Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.

article thumbnail

FogPharma pulls in $145M to support cancer drug research

BioPharma Drive: Drug Pricing

The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.

article thumbnail

FTC, in unusual move, leads Sanofi to terminate a drug research deal

BioPharma Drive: Drug Pricing

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”